Enterprise Value
935.6M
Cash
69.2M
Avg Qtr Burn
-12.05M
Short % of Float
5.27%
Insider Ownership
2.51%
Institutional Own.
73.90%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BIVIGAM® Details Autoimmune disease, Immunodeficiency, Primary humoral immunodeficiency | Approved Quarterly sales | |
ASCENIV™ Details Immunodeficiency, Autoimmune disease, Primary humoral immunodeficiency | Approved Quarterly sales | |
Nabi-HB® Details HB (Hepatitis B) | Approved Quarterly sales |